• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAA 0.00% 21.0¢

PHARMAUST LIMITED - Announcements

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for... PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.More

Announcements


PAA Phase I Monepantel Tablets Demonstrate High SafetyPRICE SENSITIVE28/03/19 download Created with Sketch. 146.46KB
PAA PharmAust Raises $1.3m in Rights IssuePRICE SENSITIVE22/03/19 download Created with Sketch. 158.69KB
PAA MPL Tablets Demonstrate Positive Performance in Phase 1PRICE SENSITIVE14/03/19 download Created with Sketch. 170.87KB
PAA PharmAust Rights Issue Reaches Minimum SubscriptionPRICE SENSITIVE12/03/19 download Created with Sketch. 152.62KB
PAA PharmAust Intellectual Property Update05/03/19 download Created with Sketch. 201.6KB
PAA Appendix 4D & Financial ReportPRICE SENSITIVE01/03/19 download Created with Sketch. 1.03MB
PAA Offer Document - Rights IssuePRICE SENSITIVE26/02/19 download Created with Sketch. 266.27KB
PAA Phase I Dog Trial with New Monepantel Tablets CommencesPRICE SENSITIVE20/02/19 download Created with Sketch. 175.38KB
PAA Letter to Shareholders19/02/19 download Created with Sketch. 200.33KB
PAA Epichem Awarded One-Year Contract Extension from DNDiPRICE SENSITIVE18/02/19 download Created with Sketch. 126.56KB
PAA Letter to Optionholders18/02/19 download Created with Sketch. 207.9KB
PAA Section 708AA Notice18/02/19 download Created with Sketch. 199.47KB
PAA Appendix 3B18/02/19 download Created with Sketch. 444.71KB
PAA Non-Renounceable Rights OfferPRICE SENSITIVE18/02/19 download Created with Sketch. 194.56KB
PAA Appendix 3B - Amendment14/02/19 download Created with Sketch. 499.21KB
PAA PAA Completes Successful Taste Mask Testing of New TabletPRICE SENSITIVE11/02/19 download Created with Sketch. 187.81KB
PAA Section 708 Notice07/02/19 download Created with Sketch. 129.49KB
PAA Appendix 3B07/02/19 download Created with Sketch. 430.58KB
PAA PharmAust Signs Agreement for US Phase I Trials in DogsPRICE SENSITIVE07/02/19 download Created with Sketch. 178.54KB
PAA PharmAust Completes Scaled Manufacture of Monepantel TabletsPRICE SENSITIVE07/02/19 download Created with Sketch. 179.84KB
PAA PharmAust Appendix 4C and Shareholders' UpdatePRICE SENSITIVE31/01/19 download Created with Sketch. 347.78KB
PAA PharmAust and Elanco Execute Data Sharing AgreementPRICE SENSITIVE29/01/19 download Created with Sketch. 144.22KB
PAA Optimisation of Monepantel UptakePRICE SENSITIVE21/01/19 download Created with Sketch. 176.98KB
PAA Monepantel Principal Metabolite Shows Anti-Cancer ActivityPRICE SENSITIVE14/01/19 download Created with Sketch. 177.85KB
PAA PharmAust Develops Method for MPL/Analogue ManufacturePRICE SENSITIVE03/12/18 download Created with Sketch. 165.01KB
PAA GMP Tablet Manufacture Commences for Canine Clinical TrialsPRICE SENSITIVE13/11/18 download Created with Sketch. 161.32KB
PAA Results of Annual General Meeting09/11/18 download Created with Sketch. 133.14KB
PAA AGM Presentation09/11/18 download Created with Sketch. 1.17MB
PAA Appendix 4C & Company Update - Sep 2018PRICE SENSITIVE01/11/18 download Created with Sketch. 348.47KB
PAA PharmAust Develops GMP Method for Monepantel AnaloguesPRICE SENSITIVE29/10/18 download Created with Sketch. 160.25KB
PAA PharmAust Progresses Monepantel Tablet Program for CancerPRICE SENSITIVE15/10/18 download Created with Sketch. 153.6KB
PAA Notice of Annual General Meeting/Proxy Form10/10/18 download Created with Sketch. 723.22KB
PAA Appendix 3X & 3Z08/10/18 download Created with Sketch. 212.05KB
PAA Neville Bassett AM appointed to PharmAust Board02/10/18 download Created with Sketch. 191.15KB
PAA Appendix 4G & Corporate Governance Statement01/10/18 download Created with Sketch. 592.56KB
PAA Annual Report01/10/18 download Created with Sketch. 1.51MB
PAA Olivia Newton-John Cancer Reseach Institute collaborationPRICE SENSITIVE10/09/18 download Created with Sketch. 70.37KB
PAA Reformulation of MPL into tablet form for upcoming trialsPRICE SENSITIVE04/09/18 download Created with Sketch. 68KB
PAA Preliminary Final ReportPRICE SENSITIVE03/09/18 download Created with Sketch. 122.72KB
PAA Appendix 4C & Company Update - June 18PRICE SENSITIVE31/07/18 download Created with Sketch. 410.77KB
PAA Epichem gains prestigious international ISO accreditationPRICE SENSITIVE02/07/18 download Created with Sketch. 70.27KB
PAA Becoming a substantial holder29/06/18 download Created with Sketch. 886.31KB
PAA Change of Director's Interest Notice - Bishop (re-release)27/06/18 download Created with Sketch. 37.34KB
PAA Change of Director's Interest Notice - Bishop27/06/18 download Created with Sketch. 33.05KB
PAA Change of Director's Interest Notice - Wright26/06/18 download Created with Sketch. 33.72KB
PAA Epichem Awarded Major US Drug Discovery Contract ExtensionPRICE SENSITIVE07/06/18 download Created with Sketch. 33.8KB
PAA MPL successfully reformulated for canine clinical trialsPRICE SENSITIVE28/05/18 download Created with Sketch. 31.72KB
PAA Chief Executive Officer resignsPRICE SENSITIVE21/05/18 download Created with Sketch. 143.89KB
PAA Appendix 4C & Company UpdatePRICE SENSITIVE01/05/18 download Created with Sketch. 175.42KB
PAA PharmAust enters option to license agreement with ElancoPRICE SENSITIVE18/04/18 download Created with Sketch. 73.91KB
PAA Trading HaltPRICE SENSITIVE16/04/18 download Created with Sketch. 298.33KB
PAA Wayne Best appointed Epichem Chairman and Dr Keenan as CEO10/04/18 download Created with Sketch. 78.21KB
PAA Cleansing Notice20/03/18 download Created with Sketch. 74.01KB
PAA Change of Director's Interest Notice x 316/03/18 download Created with Sketch. 67.93KB
PAA Appendix 3B & s708 notice16/03/18 download Created with Sketch. 154.86KB
PAA Collaboration with Olivia Newton-John Cancer Research Inst14/03/18 download Created with Sketch. 307.06KB
PAA Appendix 4D and Half Yearly Report & AccountsPRICE SENSITIVE28/02/18 download Created with Sketch. 276.41KB
PAA PharmAust receives $354k R&D Tax Incentive RefundPRICE SENSITIVE28/02/18 download Created with Sketch. 143.27KB
PAA Results of General Meeting26/02/18 download Created with Sketch. 36.5KB
PAA Appendix 4C - Quarterly Report & Shareholders UpdatePRICE SENSITIVE31/01/18 download Created with Sketch. 283.12KB
PAA Monepantel reformulation successfully improves dose & tastePRICE SENSITIVE30/01/18 download Created with Sketch. 133.5KB
PAA Notice of General Meeting/Proxy Form29/01/18 download Created with Sketch. 115.44KB
PAA Epichem Awarded One Year Contract Extension from DNDiPRICE SENSITIVE18/01/18 download Created with Sketch. 130.71KB
PAA International Vet Cancer Specialist Joins PAA Advisory Board18/12/17 download Created with Sketch. 142.35KB
PAA Appendix 3B & s708 notice14/12/17 download Created with Sketch. 204.65KB
PAA Phase II Dog Lymphoma Trial Confirms MPL Clinical BenefitPRICE SENSITIVE13/12/17 download Created with Sketch. 152.19KB
PAA PharmAust Raises $1.873m via an Oversubscribed PlacementPRICE SENSITIVE06/12/17 download Created with Sketch. 72.32KB
PAA Trading HaltPRICE SENSITIVE01/12/17 download Created with Sketch. 226.55KB
PAA Results of Annual General Meeting29/11/17 download Created with Sketch. 33.99KB
PAA PharmAust AGM Presentation29/11/17 download Created with Sketch. 997.81KB
PAA PharmAust Launches New Corporate Website29/11/17 download Created with Sketch. 63.27KB
PAA New MPL analogues show greater anti-cancer activityPRICE SENSITIVE23/11/17 download Created with Sketch. 67.14KB
PAA New drugs patented for cancer in USAPRICE SENSITIVE16/11/17 download Created with Sketch. 131.45KB
PAA Epichem Update - progress on milestones and revenue targetsPRICE SENSITIVE01/11/17 download Created with Sketch. 70.13KB
PAA Notice of Annual General Meeting/Proxy Form27/10/17 download Created with Sketch. 108.97KB
PAA Appendix 4C - Quarterly Report & Brief Company UpdatePRICE SENSITIVE26/10/17 download Created with Sketch. 238.2KB
PAA Monepantel reformulation project continues to progressPRICE SENSITIVE17/10/17 download Created with Sketch. 68.21KB
PAA New patent secured in US for non-cancer applicationsPRICE SENSITIVE10/10/17 download Created with Sketch. 468.93KB
PAA Two key appointments to bolster PharmAust vet drug programs03/10/17 download Created with Sketch. 182.76KB
PAA Reformulation project achieves first milestones and on-trackPRICE SENSITIVE20/09/17 download Created with Sketch. 157.07KB
PAA PharmAust secures core Europe patentPRICE SENSITIVE12/09/17 download Created with Sketch. 382.22KB
PAA PharmAust & Nihon Nohyaku Japan Enter Assignment AgreementPRICE SENSITIVE04/09/17 download Created with Sketch. 145.14KB
PAA Appendix 4G & Corporate Governance Statement01/09/17 download Created with Sketch. 312.38KB
PAA Appendix 4E & Full Year Statutory Accounts 2017PRICE SENSITIVE01/09/17 download Created with Sketch. 902.47KB
PAA PharmAust Investor Presentation30/08/17 download Created with Sketch. 4.93MB
PAA PharmAust Shareholders UpdatePRICE SENSITIVE22/08/17 download Created with Sketch. 240.78KB
PAA Appendix 4C - Quarterly Report & Brief Company UpdatePRICE SENSITIVE01/08/17 download Created with Sketch. 145.37KB
PAA Epichem reports record $3m revenues & expands laboratoryPRICE SENSITIVE17/07/17 download Created with Sketch. 71.54KB
PAA Canadian-based specialists to reformulate monepantelPRICE SENSITIVE27/06/17 download Created with Sketch. 92.31KB
PAA New European patent granted for non-cancer applicationsPRICE SENSITIVE08/06/17 download Created with Sketch. 103.15KB
PAA PharmAust secures core patent in JapanPRICE SENSITIVE06/06/17 download Created with Sketch. 89.95KB
PAA PharmAust Shareholders Update and Roadmap30/05/17 download Created with Sketch. 190.62KB
PAA PharmAust Investor Presentation - May 201722/05/17 download Created with Sketch. 1.15MB
PAA Phase II trial prelim results demonstrate clinical benefitPRICE SENSITIVE19/05/17 download Created with Sketch. 96.29KB
PAA New patent granted for non-cancer applicationsPRICE SENSITIVE17/05/17 download Created with Sketch. 87.55KB
PAA PharmAust secures core China patentPRICE SENSITIVE05/05/17 download Created with Sketch. 84.52KB
PAA Appendix 4C - Quarterly Report & Company Update - March 2017PRICE SENSITIVE13/04/17 download Created with Sketch. 521.31KB
PAA Dr Richard Mollard appointed as Chief Scientific Officer08/03/17 download Created with Sketch. 354.55KB
PAA PharmAust raises a further $534k03/03/17 download Created with Sketch. 1.1MB
PAA Dr Richard Hopkins Appointed as CEO of PharmAustPRICE SENSITIVE01/03/17 download Created with Sketch. 430.76KB
PAA Phase I Monepantel Tablets Demonstrate High Safety
28/03/19PRICE SENSITIVE download Created with Sketch. 146.46KB
PAA PharmAust Raises $1.3m in Rights Issue
22/03/19PRICE SENSITIVE download Created with Sketch. 158.69KB
PAA MPL Tablets Demonstrate Positive Performance in Phase 1
14/03/19PRICE SENSITIVE download Created with Sketch. 170.87KB
PAA PharmAust Rights Issue Reaches Minimum Subscription
12/03/19PRICE SENSITIVE download Created with Sketch. 152.62KB
PAA PharmAust Intellectual Property Update
05/03/19 download Created with Sketch. 201.6KB
PAA Appendix 4D & Financial Report
01/03/19PRICE SENSITIVE download Created with Sketch. 1.03MB
PAA Offer Document - Rights Issue
26/02/19PRICE SENSITIVE download Created with Sketch. 266.27KB
PAA Phase I Dog Trial with New Monepantel Tablets Commences
20/02/19PRICE SENSITIVE download Created with Sketch. 175.38KB
PAA Letter to Shareholders
19/02/19 download Created with Sketch. 200.33KB
PAA Epichem Awarded One-Year Contract Extension from DNDi
18/02/19PRICE SENSITIVE download Created with Sketch. 126.56KB
PAA Letter to Optionholders
18/02/19 download Created with Sketch. 207.9KB
PAA Section 708AA Notice
18/02/19 download Created with Sketch. 199.47KB
PAA Appendix 3B
18/02/19 download Created with Sketch. 444.71KB
PAA Non-Renounceable Rights Offer
18/02/19PRICE SENSITIVE download Created with Sketch. 194.56KB
PAA Appendix 3B - Amendment
14/02/19 download Created with Sketch. 499.21KB
PAA PAA Completes Successful Taste Mask Testing of New Tablet
11/02/19PRICE SENSITIVE download Created with Sketch. 187.81KB
PAA Section 708 Notice
07/02/19 download Created with Sketch. 129.49KB
PAA Appendix 3B
07/02/19 download Created with Sketch. 430.58KB
PAA PharmAust Signs Agreement for US Phase I Trials in Dogs
07/02/19PRICE SENSITIVE download Created with Sketch. 178.54KB
PAA PharmAust Completes Scaled Manufacture of Monepantel Tablets
07/02/19PRICE SENSITIVE download Created with Sketch. 179.84KB
PAA PharmAust Appendix 4C and Shareholders' Update
31/01/19PRICE SENSITIVE download Created with Sketch. 347.78KB
PAA PharmAust and Elanco Execute Data Sharing Agreement
29/01/19PRICE SENSITIVE download Created with Sketch. 144.22KB
PAA Optimisation of Monepantel Uptake
21/01/19PRICE SENSITIVE download Created with Sketch. 176.98KB
PAA Monepantel Principal Metabolite Shows Anti-Cancer Activity
14/01/19PRICE SENSITIVE download Created with Sketch. 177.85KB
PAA PharmAust Develops Method for MPL/Analogue Manufacture
03/12/18PRICE SENSITIVE download Created with Sketch. 165.01KB
PAA GMP Tablet Manufacture Commences for Canine Clinical Trials
13/11/18PRICE SENSITIVE download Created with Sketch. 161.32KB
PAA Results of Annual General Meeting
09/11/18 download Created with Sketch. 133.14KB
PAA AGM Presentation
09/11/18 download Created with Sketch. 1.17MB
PAA Appendix 4C & Company Update - Sep 2018
01/11/18PRICE SENSITIVE download Created with Sketch. 348.47KB
PAA PharmAust Develops GMP Method for Monepantel Analogues
29/10/18PRICE SENSITIVE download Created with Sketch. 160.25KB
PAA PharmAust Progresses Monepantel Tablet Program for Cancer
15/10/18PRICE SENSITIVE download Created with Sketch. 153.6KB
PAA Notice of Annual General Meeting/Proxy Form
10/10/18 download Created with Sketch. 723.22KB
PAA Appendix 3X & 3Z
08/10/18 download Created with Sketch. 212.05KB
PAA Neville Bassett AM appointed to PharmAust Board
02/10/18 download Created with Sketch. 191.15KB
PAA Appendix 4G & Corporate Governance Statement
01/10/18 download Created with Sketch. 592.56KB
PAA Annual Report
01/10/18 download Created with Sketch. 1.51MB
PAA Olivia Newton-John Cancer Reseach Institute collaboration
10/09/18PRICE SENSITIVE download Created with Sketch. 70.37KB
PAA Reformulation of MPL into tablet form for upcoming trials
04/09/18PRICE SENSITIVE download Created with Sketch. 68KB
PAA Preliminary Final Report
03/09/18PRICE SENSITIVE download Created with Sketch. 122.72KB
PAA Appendix 4C & Company Update - June 18
31/07/18PRICE SENSITIVE download Created with Sketch. 410.77KB
PAA Epichem gains prestigious international ISO accreditation
02/07/18PRICE SENSITIVE download Created with Sketch. 70.27KB
PAA Becoming a substantial holder
29/06/18 download Created with Sketch. 886.31KB
PAA Change of Director's Interest Notice - Bishop (re-release)
27/06/18 download Created with Sketch. 37.34KB
PAA Change of Director's Interest Notice - Bishop
27/06/18 download Created with Sketch. 33.05KB
PAA Change of Director's Interest Notice - Wright
26/06/18 download Created with Sketch. 33.72KB
PAA Epichem Awarded Major US Drug Discovery Contract Extension
07/06/18PRICE SENSITIVE download Created with Sketch. 33.8KB
PAA MPL successfully reformulated for canine clinical trials
28/05/18PRICE SENSITIVE download Created with Sketch. 31.72KB
PAA Chief Executive Officer resigns
21/05/18PRICE SENSITIVE download Created with Sketch. 143.89KB
PAA Appendix 4C & Company Update
01/05/18PRICE SENSITIVE download Created with Sketch. 175.42KB
PAA PharmAust enters option to license agreement with Elanco
18/04/18PRICE SENSITIVE download Created with Sketch. 73.91KB
PAA Trading Halt
16/04/18PRICE SENSITIVE download Created with Sketch. 298.33KB
PAA Wayne Best appointed Epichem Chairman and Dr Keenan as CEO
10/04/18 download Created with Sketch. 78.21KB
PAA Cleansing Notice
20/03/18 download Created with Sketch. 74.01KB
PAA Change of Director's Interest Notice x 3
16/03/18 download Created with Sketch. 67.93KB
PAA Appendix 3B & s708 notice
16/03/18 download Created with Sketch. 154.86KB
PAA Collaboration with Olivia Newton-John Cancer Research Inst
14/03/18 download Created with Sketch. 307.06KB
PAA Appendix 4D and Half Yearly Report & Accounts
28/02/18PRICE SENSITIVE download Created with Sketch. 276.41KB
PAA PharmAust receives $354k R&D Tax Incentive Refund
28/02/18PRICE SENSITIVE download Created with Sketch. 143.27KB
PAA Results of General Meeting
26/02/18 download Created with Sketch. 36.5KB
PAA Appendix 4C - Quarterly Report & Shareholders Update
31/01/18PRICE SENSITIVE download Created with Sketch. 283.12KB
PAA Monepantel reformulation successfully improves dose & taste
30/01/18PRICE SENSITIVE download Created with Sketch. 133.5KB
PAA Notice of General Meeting/Proxy Form
29/01/18 download Created with Sketch. 115.44KB
PAA Epichem Awarded One Year Contract Extension from DNDi
18/01/18PRICE SENSITIVE download Created with Sketch. 130.71KB
PAA International Vet Cancer Specialist Joins PAA Advisory Board
18/12/17 download Created with Sketch. 142.35KB
PAA Appendix 3B & s708 notice
14/12/17 download Created with Sketch. 204.65KB
PAA Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit
13/12/17PRICE SENSITIVE download Created with Sketch. 152.19KB
PAA PharmAust Raises $1.873m via an Oversubscribed Placement
06/12/17PRICE SENSITIVE download Created with Sketch. 72.32KB
PAA Trading Halt
01/12/17PRICE SENSITIVE download Created with Sketch. 226.55KB
PAA Results of Annual General Meeting
29/11/17 download Created with Sketch. 33.99KB
PAA PharmAust AGM Presentation
29/11/17 download Created with Sketch. 997.81KB
PAA PharmAust Launches New Corporate Website
29/11/17 download Created with Sketch. 63.27KB
PAA New MPL analogues show greater anti-cancer activity
23/11/17PRICE SENSITIVE download Created with Sketch. 67.14KB
PAA New drugs patented for cancer in USA
16/11/17PRICE SENSITIVE download Created with Sketch. 131.45KB
PAA Epichem Update - progress on milestones and revenue targets
01/11/17PRICE SENSITIVE download Created with Sketch. 70.13KB
PAA Notice of Annual General Meeting/Proxy Form
27/10/17 download Created with Sketch. 108.97KB
PAA Appendix 4C - Quarterly Report & Brief Company Update
26/10/17PRICE SENSITIVE download Created with Sketch. 238.2KB
PAA Monepantel reformulation project continues to progress
17/10/17PRICE SENSITIVE download Created with Sketch. 68.21KB
PAA New patent secured in US for non-cancer applications
10/10/17PRICE SENSITIVE download Created with Sketch. 468.93KB
PAA Two key appointments to bolster PharmAust vet drug programs
03/10/17 download Created with Sketch. 182.76KB
PAA Reformulation project achieves first milestones and on-track
20/09/17PRICE SENSITIVE download Created with Sketch. 157.07KB
PAA PharmAust secures core Europe patent
12/09/17PRICE SENSITIVE download Created with Sketch. 382.22KB
PAA PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement
04/09/17PRICE SENSITIVE download Created with Sketch. 145.14KB
PAA Appendix 4G & Corporate Governance Statement
01/09/17 download Created with Sketch. 312.38KB
PAA Appendix 4E & Full Year Statutory Accounts 2017
01/09/17PRICE SENSITIVE download Created with Sketch. 902.47KB
PAA PharmAust Investor Presentation
30/08/17 download Created with Sketch. 4.93MB
PAA PharmAust Shareholders Update
22/08/17PRICE SENSITIVE download Created with Sketch. 240.78KB
PAA Appendix 4C - Quarterly Report & Brief Company Update
01/08/17PRICE SENSITIVE download Created with Sketch. 145.37KB
PAA Epichem reports record $3m revenues & expands laboratory
17/07/17PRICE SENSITIVE download Created with Sketch. 71.54KB
PAA Canadian-based specialists to reformulate monepantel
27/06/17PRICE SENSITIVE download Created with Sketch. 92.31KB
PAA New European patent granted for non-cancer applications
08/06/17PRICE SENSITIVE download Created with Sketch. 103.15KB
PAA PharmAust secures core patent in Japan
06/06/17PRICE SENSITIVE download Created with Sketch. 89.95KB
PAA PharmAust Shareholders Update and Roadmap
30/05/17 download Created with Sketch. 190.62KB
PAA PharmAust Investor Presentation - May 2017
22/05/17 download Created with Sketch. 1.15MB
PAA Phase II trial prelim results demonstrate clinical benefit
19/05/17PRICE SENSITIVE download Created with Sketch. 96.29KB
PAA New patent granted for non-cancer applications
17/05/17PRICE SENSITIVE download Created with Sketch. 87.55KB
PAA PharmAust secures core China patent
05/05/17PRICE SENSITIVE download Created with Sketch. 84.52KB
PAA Appendix 4C - Quarterly Report & Company Update - March 2017
13/04/17PRICE SENSITIVE download Created with Sketch. 521.31KB
PAA Dr Richard Mollard appointed as Chief Scientific Officer
08/03/17 download Created with Sketch. 354.55KB
PAA PharmAust raises a further $534k
03/03/17 download Created with Sketch. 1.1MB
PAA Dr Richard Hopkins Appointed as CEO of PharmAust
01/03/17PRICE SENSITIVE download Created with Sketch. 430.76KB
(20min delay)
Last
21.0¢
Change
0.000(0.00%)
Mkt cap ! $93.45M
Open High Low Value Volume
21.0¢ 21.5¢ 20.5¢ $106.7K 516.1K

Buyers (Bids)

No. Vol. Price($)
2 24033 20.5¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 55077 2
View Market Depth
Last trade - 15.22pm 22/07/2024 (20 minute delay) ?
Last
21.0¢
  Change
0.000 ( 0.00 %)
Open High Low Volume
21.0¢ 21.0¢ 20.5¢ 342599
Last updated 15.22pm 22/07/2024 ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.